Amphastar Pharma (AMPH) Tops Q2 EPS by 2c

Amphastar Pharma (NASDAQ: AMPH) reported Q2 EPS of ($0.09), $0.02 better than the analyst estimate of ($0.11). Revenue for the quarter came in at $53.85 million versus the consensus estimate of $55.7 million.

For earnings history and earnings-related data on Amphastar Pharma (AMPH) click here.

You May Also Be Interested In

• Baird on Nurix (NRIX) Earnings Amid 7% Drop: '2Q Print Solid as Breadth of Development Expands'
• Goldman Sachs reports global fund inflows for week of July 8
• JPMorgan Upgrades Largan Precision Co Ltd. (3008:TT) to Overweight